Malignant germ cell tumor of the cervix uteri

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:213837C53.0C53.1C53.8
Who is this for?
Show terms as
1FDA treatments8Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Malignant germ cell tumor of the cervix uteri is an extremely rare neoplasm in which germ cell-derived malignant cells arise within the uterine cervix. Germ cell tumors more commonly occur in the ovaries or extragonadal sites, making cervical localization exceptionally unusual. Histological subtypes that have been reported at this site include yolk sac tumor (endodermal sinus tumor), choriocarcinoma, embryonal carcinoma, and mixed germ cell tumors. These tumors primarily affect the reproductive system and may present with abnormal vaginal bleeding, a cervical mass, pelvic pain, or vaginal discharge. Due to the rarity of this condition, patients may initially be misdiagnosed with more common cervical malignancies such as squamous cell carcinoma or adenocarcinoma. The disease predominantly affects younger women, including adolescents and women of reproductive age, which is consistent with the general age distribution of germ cell tumors. Diagnosis typically requires histopathological examination with immunohistochemical staining, and serum tumor markers such as alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (beta-hCG) may be elevated depending on the histological subtype. Imaging studies including MRI and CT scans are used for staging and to assess the extent of disease. Treatment approaches are largely extrapolated from experience with ovarian germ cell tumors and other cervical malignancies, given the lack of large clinical series. Management generally involves a combination of surgery and platinum-based chemotherapy (such as BEP: bleomycin, etoposide, and cisplatin). Radiation therapy may also be considered in certain cases. Prognosis varies depending on the stage at diagnosis, histological subtype, and response to treatment, but germ cell tumors in general tend to be chemosensitive, offering potential for favorable outcomes when diagnosed and treated early.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jan 2026MRinRT: Swansea University and SWWCC Collaboration Study.

Swansea Bay University Health Board

TrialNOT YET RECRUITING
Nov 2025Exploratory Study of Inhaled Afatinib Dimaleate PK Profile

Petrov, Andrey — PHASE1

TrialNOT YET RECRUITING
Sep 2025Contrast-enhanced Ultrasound for Sentinel Node Detection

The Netherlands Cancer Institute — PHASE2, PHASE3

TrialRECRUITING
Dec 2024EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Case Comprehensive Cancer Center — NA

TrialRECRUITING
May 2024Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

Charite University, Berlin, Germany — PHASE2

TrialNOT YET RECRUITING
Apr 2024A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Ipsen — PHASE1, PHASE2

TrialRECRUITING
Jan 2024A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Aug 2023Survival Monitoring in Russian Cancer Registries

N.N. Petrov National Medical Research Center of Oncology

TrialACTIVE NOT RECRUITING
Mar 2023Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

TILT Biotherapeutics Ltd. — PHASE1

TrialACTIVE NOT RECRUITING
Feb 2022A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Amgen — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Lynparza

olaparib· AstraZeneca Pharmaceuticals LP
for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative high risk early breast cancer who have been treated with neoadjuvant or adju

for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy

No actively recruiting trials found for Malignant germ cell tumor of the cervix uteri at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Malignant germ cell tumor of the cervix uteri community →

Specialists

8 foundView all specialists →
SM
Sharon Manne
Specialist
PI on 3 active trials2 Malignant germ cell tumor of the cervix uteri publications
SP
Susan K Peterson
Specialist
PI on 1 active trial17 Malignant germ cell tumor of the cervix uteri publications
MP
Merete C Wittenkamp, PT
Specialist
PI on 1 active trial
FM
Frank I Lin, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Lynparza(olaparib)AstraZeneca Pharmaceuticals LP

Exkivity

Takeda Development Center Americas, Inc.

Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Malignant germ cell tumor of the cervix uteri.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Malignant germ cell tumor of the cervix uteriForum →

No community posts yet. Be the first to share your experience with Malignant germ cell tumor of the cervix uteri.

Start the conversation →

Latest news about Malignant germ cell tumor of the cervix uteri

Disease timeline:

New recruiting trial: Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: Contrast-enhanced Ultrasound for Sentinel Node Detection

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

New recruiting trial: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

A new clinical trial is recruiting patients for Malignant germ cell tumor of the cervix uteri

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Malignant germ cell tumor of the cervix uteri

What is Malignant germ cell tumor of the cervix uteri?

Malignant germ cell tumor of the cervix uteri is an extremely rare neoplasm in which germ cell-derived malignant cells arise within the uterine cervix. Germ cell tumors more commonly occur in the ovaries or extragonadal sites, making cervical localization exceptionally unusual. Histological subtypes that have been reported at this site include yolk sac tumor (endodermal sinus tumor), choriocarcinoma, embryonal carcinoma, and mixed germ cell tumors. These tumors primarily affect the reproductive system and may present with abnormal vaginal bleeding, a cervical mass, pelvic pain, or vaginal disc

How is Malignant germ cell tumor of the cervix uteri inherited?

Malignant germ cell tumor of the cervix uteri follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Malignant germ cell tumor of the cervix uteri?

8 specialists and care centers treating Malignant germ cell tumor of the cervix uteri are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Malignant germ cell tumor of the cervix uteri?

1 patient support program are currently tracked on UniteRare for Malignant germ cell tumor of the cervix uteri. See the treatments and support programs sections for copay assistance, eligibility, and contact details.